-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor, combined with endocrine (ET) approved for the treatment of hormone receptor positive (HR)/human epidermal growth factor receptor 2 negative (HER2−) Patients with advanced breast cancer (ABC).
Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor, combined with endocrine (ET) approved for the treatment of hormone receptor positive (HR)/human epidermal growth factor receptor 2 negative (HER2−) Patients with advanced breast cancer (ABC).
The article updates the comprehensive analysis of the 5-year follow-up safety of Palbociclib combined therapy in the PALOMA series of studies.
The article updates the comprehensive analysis of the 5-year follow-up safety of Palbociclib combined therapy in the PALOMA series of studies.
Comparison of treatment duration
Comparison of treatment durationPalbociclib combined with endocrine group had any grade of neutropenia and infection were 82.
Palbociclib combined with endocrine group had any grade of neutropenia and infection were 82.
Adverse events of endocrine therapy
Adverse events of endocrine therapyAdverse events related to combination or monotherapy
Adverse events related to combination or monotherapyIn summary, through a 5-year long-term comprehensive analysis, Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer is proved to be a safe treatment.
In summary, through a 5-year long-term comprehensive analysis, Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer is proved to be a safe treatment.
ncbi.
ncbi.
nlm.
nih.
gov/?term=Finn+RS&cauthor_id=33486783">Richard S Finn,ncbi.
nlm.
nih.
gov/?term=Rugo+HS&cauthor_id=33486783">Hope S Rugo,ncbi.
nlm.
nih.
gov/?term=Gelmon+KA&cauthor_id=33486783">Karen A Gelmon , et al.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up .
.
.
5 to Years of the Follow-Up on May Oncologist 2021; 26 is (.
5): e749-e755.
doi: 10.
1002 / onco.
13684.
ncbi.
nlm.
nih.
gov/?term=Finn+RS&cauthor_id=33486783">Richard S Finn ncbi.
nlm.
nih.
gov/?term=Rugo+HS&cauthor_id=33486783">Hope S Rugo ncbi.
nlm.
nih.
gov/?term=Gelmon+KA&cauthor_id=33486783">Karen A Gelmon in this message